Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2013
At a glance
- Drugs Ranolazine (Primary)
- Indications Coronary artery disease; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms REMS
- 10 Jun 2017 Biomarkers information updated
- 10 Jul 2013 Planned End Date changed from 1 Mar 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 10 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.